Development of Pulmonary Hypertension in Over One-Third of Patients With Th/To Antibody-Positive Scleroderma in Long-Term Follow-Up.
Shashank SureshDevon CharltonErin K SnellMaureen LaffoonThomas A MedsgerLei ZhuRobyn T DomsicPublished in: Arthritis & rheumatology (Hoboken, N.J.) (2022)
This is the largest cohort of patients with anti-Th/To antibody-positive SSc with long-term follow-up data. The very high rate (38%) and associated independent risk of anti-Th/To antibody-positive patients developing PH in follow-up, particularly in WHO Group 1 PAH patients, is striking. Patients presenting with limited skin involvement should be tested for Th/To antibodies, and if present, careful monitoring for PH is warranted.
Keyphrases
- end stage renal disease
- pulmonary hypertension
- ejection fraction
- newly diagnosed
- chronic kidney disease
- peritoneal dialysis
- prognostic factors
- rheumatoid arthritis
- pulmonary artery
- coronary artery
- electronic health record
- pulmonary arterial hypertension
- big data
- idiopathic pulmonary fibrosis
- artificial intelligence